RA, Jeito and Omega back a small Swiss biotech to en­ter an I/O field paved by Adap­ti­m­mune

A li­cens­ing deal worth up to $520 mil­lion has been fu­el­ing lit­tle-known Swiss biotech CDR-Life since May 2020, but the five-year-old start­up is ready to haul in tra­di­tion­al ven­ture cap­i­tal fi­nanc­ing.

Af­ter Boe­hinger In­gel­heim ful­ly took con­trol of the duo’s col­lab­o­ra­tion on a pre­clin­i­cal an­ti­body for ge­o­graph­ic at­ro­phy — one of the lead­ing caus­es of blind­ness — last sum­mer, CDR-Life went to work find­ing in­vestors to take its plat­form for­ward in sol­id tu­mors. Fill­ing that fund­ing role are RA Cap­i­tal Man­age­ment and Rafaèle Tord­j­man’s Jeito Cap­i­tal, who are co-lead­ing CDR-Life’s $76 mil­lion Se­ries A with help from Otel­lo Stam­pac­chia’s Omega Funds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER